Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences announced the presentation of initial safety data from its Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the upcoming EASL Congress. The data suggests positive outcomes for the gene editing therapy aimed at addressing hepatitis B. This presentation underscores the potential of Precision's ARCUS platform in treating diseases with significant unmet needs.
Price reaction · baseline $5.1 (2025-05-06 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial safety data from the trial shows promising results.
  • The presentation at EASL highlights the company's innovative approach.
  • The ARCUS platform is positioned to address high unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 7, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will present initial

Frequently Asked Questions

What is the ELIMINATE-B trial?

The ELIMINATE-B trial is a Phase 1 study evaluating PBGENE-HBV for hepatitis B.

When will the safety data be presented?

The initial safety data will be presented at the EASL Congress in 2025.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What is the focus of PBGENE-HBV?

PBGENE-HBV aims to address the high unmet medical need in hepatitis B treatment.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences EASL 2025 gene editing PBGENE-HBV
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →